Patents by Inventor George Doss
George Doss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7728141Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: October 29, 2004Date of Patent: June 1, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: John S. Debenham, George A. Doss, Christina B. Madsen-Duggan, Thomas F. Walsh
-
Patent number: 7576239Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: January 14, 2008Date of Patent: August 18, 2009Assignee: Merck & Co., Inc.Inventors: Linus S. Lin, William K. Hagmann, Sanjeev Kumar, Wenji Yin, George Doss
-
Publication number: 20080194645Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: January 14, 2008Publication date: August 14, 2008Inventors: Linus S. Lin, William K. Hagmann, Sanjeev Kumar, Wenji Yin, George Doss
-
Patent number: 7348456Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: December 15, 2003Date of Patent: March 25, 2008Assignee: Merck & Co., Inc.Inventors: Linus S. Lin, William K. Hagmann, Sanjeev Kumar, Wenji Yin, George Doss
-
Publication number: 20070032517Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: October 29, 2004Publication date: February 8, 2007Inventors: John Debenham, George Doss, Christina Madsen-Duggan, Thomas Walsh
-
Publication number: 20060106071Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: December 15, 2003Publication date: May 18, 2006Inventors: Linus Lin, William Hagmann, Sanjeev Kumar, Wenji Yin, George Doss
-
Patent number: 5359096Abstract: New cholesterol lowering compounds are formed from the photochemical treatment of the zaragozic acids.Type: GrantFiled: November 20, 1992Date of Patent: October 25, 1994Assignee: Merck & Co., Inc.Inventors: Laszlo R. Treiber, Byron H. Arison, Shieh-Shung T. Chen, George A. Doss, Leeyuan Huang, John G. MacConnell
-
Patent number: 5317031Abstract: Cholesterol lowering compounds and compositions are formed from the photochemical treatment of the Zaragozic Acids followed by esterification. These compounds and compositions are active squalene synthetase inhibitors useful in the treatment of hypercholesterolemia.Type: GrantFiled: November 24, 1992Date of Patent: May 31, 1994Assignee: Merck & Co., Inc.Inventors: John G. MacConnell, Byron H. Arison, George A. Doss, Richard L. Monaghan
-
Patent number: 5250563Abstract: Novel cytochalasins are the biotransformed products after incubation with a substrate in a culture of the microorganism Kibdelosporangium sp. (Merck Culture Collection MA 6559), ATCC No. 53771. The compounds of the present invention inhibit HIV protease and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.Type: GrantFiled: September 25, 1992Date of Patent: October 5, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George A. Doss, Russell B. Lingham
-
Patent number: 5215900Abstract: Fermentation of the microorganism Streptomyces sp. (MA6804), ATTC No. 55095, in the presence of the HIV reverse transcriptase inhibitor ##STR1## yields a 5-(1-hydroxy)ethyl analog which is useful in the prevention or treatment of infection by HIV and the treatment of AIDS.Type: GrantFiled: June 7, 1991Date of Patent: June 1, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss
-
Patent number: 5194379Abstract: Fermentation of the microoganism Actinoplanacete sp. in the presence of the angiotensin II receptor antagonist, 5,7-dimethyl-2-ethyl-3-((2'-tetrazol-5-yl)biphenyl-4-yl)methyl-3H-imidazo[ 4,5-b]pyridine, compound III, ##STR1## yields 2-ethyl-5-hydroxymethyl-7-methyl-3-((2'-tetrazol-5-yl)biphenyl-4-yl)methyl -3H-imidazo[4,5-b]pyridine, compound I, and 2-ethyl-7-hydroxymethyl-5-methyl-3-(2'-tetrazol-3-((2'-tetrazol-5-yl)biphe nyl-4-yl)methy-3H-imidazo[4,5-b]pyridine, compound II, ##STR2## both of which are angiotensin II receptor antagonists useful in the treatment of hypertension and congestive heart failure and other indications known to respond to angiotensin II antagonists.Type: GrantFiled: April 29, 1991Date of Patent: March 16, 1993Assignee: Merck & Co., Inc.Inventors: Sheih-Shung T. Chen, George Doss
-
Patent number: 5185251Abstract: Fermentation of the microorganism Actinoplanacete sp. (MA6559), ATTC No. 53771, in the presence of the HIV reverse transcriptase inhibitor ##STR1## yields 3-[2-(benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2(1H)-pyridinone and 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-hydroxymethyl-2(1H)-pyridinone, both of which are useful in the prevention or treatment of infection by HIV and the treatment of AIDS.Type: GrantFiled: June 7, 1991Date of Patent: February 9, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss
-
Patent number: 5132216Abstract: Fermentation of the microorganism Streptomyces sp. MA6744 (ATCC No. 55041) in the presence of the Angiotensin II (A II) receptor antagonist ##STR1## yields a 7-hydroxymethyl, a 5,7-dihydroxymethyl, a 7-carboxy and a 1'-hydroxy-5-hydroxymethyl analog, all of which are also A II antagonists useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: June 7, 1991Date of Patent: July 21, 1992Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss
-
Patent number: 5085992Abstract: Fermentation of the microorganism Streptomyces sp. MA6751 (ATCC No. 55043) in the presence of the Angiotensin II (A II) receptor antagonist ##STR1## yields an N2-tetrazole .beta.-glucuronide analog which is also an A II antagonist useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: February 25, 1991Date of Patent: February 4, 1992Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss
-
Patent number: 5066586Abstract: Novel biotransformation compounds I, II, III and IV are prepared by fermenting 3-[(2'-tetrazol-5-yl-biphenyl-4-yl) methyl]-7-methyl-2-propyl-3H-imidzao [4,5-b]pyridine in a culture of Streptomyces sp., Accession Number ATCC 55041. ##STR1## These novel compounds are Angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: August 20, 1990Date of Patent: November 19, 1991Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss
-
Patent number: 5057522Abstract: Fermentation of the microorganism Streptomyces sp.Type: GrantFiled: July 19, 1990Date of Patent: October 15, 1991Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George Doss